Literature DB >> 19759470

Drug resistant Mycobacterium tuberculosis in Mexico.

Jorge Zazueta-Beltran1, Claudia León-Sicairos, Adrián Canizalez-Roman.   

Abstract

Tuberculosis (TB) remains a serious public health problem, worsened by an increased frequency of multidrug-resistant (MDR) Mycobacterium tuberculosis strains. The World Health Organization (WHO) and the International Union Against Tuberculosis and Lung Disease (IUATLD) launched the Global Project on Anti-Tuberculosis Drug Resistance Surveillance to measure the prevalence of drug resistance. Data from the global reports on resistance to anti-tuberculosis (anti-TB) drugs have shown that drug resistance still presents worldwide and that MDR-TB is present in almost all the world. Though the Global Project (WHO) has been operating since 1994, very few countries and states have reported new information. Data from repeated surveys employing comparable methodologies over several years are essential to determine with any certainty in which direction the prevalence of drug resistance is moving. Drug-resistant tuberculosis and MDR-TB have been identified in Mexico, even with the existence of a National Tuberculosis Program based on Directly Observed Treatment, Short-course (DOTS). This review discusses available surveillance data on drug susceptibility data for TB in different states of Mexico.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19759470     DOI: 10.3855/jidc.31

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  5 in total

1.  Outcomes of multidrug-resistant tuberculosis among binational cases in El Paso, Texas.

Authors:  Gustavo Ferrer; Carlos Acuna-Villaorduna; Miguel Escobedo; Esteban Vlasich; Manuel Rivera
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

2.  Neurobrucellosis: Unexpected Answer From Metagenomic Next-Generation Sequencing.

Authors:  Kanokporn Mongkolrattanothai; Samia N Naccache; Jeffrey M Bender; Erik Samayoa; Elizabeth Pham; Guixia Yu; Jennifer Dien Bard; Steve Miller; Grace Aldrovandi; Charles Y Chiu
Journal:  J Pediatric Infect Dis Soc       Date:  2017-11-24       Impact factor: 3.164

3.  Social, economic, and psychological impacts of MDR-TB treatment in Tijuana, Mexico: a patient's perspective.

Authors:  M D Morris; L Quezada; P Bhat; K Moser; J Smith; H Perez; R Laniado-Laborin; J Estrada-Guzman; T C Rodwell
Journal:  Int J Tuberc Lung Dis       Date:  2013-07       Impact factor: 2.373

4.  Trends of Mycobacterium bovis Isolation and First-Line Anti-tuberculosis Drug Susceptibility Profile: A Fifteen-Year Laboratory-Based Surveillance.

Authors:  Miriam Bobadilla-del Valle; Pedro Torres-González; Miguel Enrique Cervera-Hernández; Areli Martínez-Gamboa; Brenda Crabtree-Ramirez; Bárbara Chávez-Mazari; Narciso Ortiz-Conchi; Luis Rodríguez-Cruz; Axel Cervantes-Sánchez; Tomasa Gudiño-Enríquez; Carmen Cinta-Severo; José Sifuentes-Osornio; Alfredo Ponce de León
Journal:  PLoS Negl Trop Dis       Date:  2015-09-30

5.  Genetic diversity of Mycobacterium tuberculosis from Guadalajara, Mexico and identification of a rare multidrug resistant Beijing genotype.

Authors:  Samantha Flores-Treviño; Rayo Morfín-Otero; Eduardo Rodríguez-Noriega; Esteban González-Díaz; Héctor R Pérez-Gómez; Virgilio Bocanegra-García; Lucio Vera-Cabrera; Elvira Garza-González
Journal:  PLoS One       Date:  2015-02-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.